A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.
Andrew Dauber, Ravi Savarirayan, Philippe M Campeau et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3, multicenter, randomized, placebo-controlled trial evaluated once-daily vosoritide in children aged 3 to less than 18 years with hypochondroplasia. After 52 weeks, annualized growth velocity increased by a least-squares mean of 1.95 cm/year from baseline with vosoritide, compared with a decrease of 0.39 cm/year with placebo; the between-group difference was 2.33 cm/year (95% CI, 1.85-2.82; P<0.0001). Adverse events were reported in both groups, with no grade 3 or higher events, treatment discontinuations due to adverse events, or deaths.
Key findings
- At week 52, the annualized growth velocity difference between vosoritide and placebo was 2.33 cm/year (95% CI, 1.85-2.82; P<0.0001).
- At least one adverse event occurred in 87.8% of participants receiving vosoritide and 72.5% receiving placebo.
- No grade 3 or higher adverse events, adverse-event-related treatment discontinuations, or deaths were reported.
Why it matters
Hypochondroplasia has no available targeted therapy, and this randomized trial found that vosoritide increased linear growth over one year compared with placebo. The findings provide clinical evidence for a potential treatment option in this population, while the reported outcome is growth velocity and the abstract does not establish longer-term effects on health or function.
What to keep in mind
Follow-up was limited to 52 weeks, and the reported primary outcome was annualized growth velocity; longer-term clinical outcomes are not provided in the abstract.